Ellis Levine

MD
Medical Oncology
2023 Buffalo Spree Top Doctors Badge

Dr. Levine is a Buffalo Spree Top Doctor! See all of our physicians who made this year's list.

Top Doctors 2023

Cancers Treated:

Breast Penile Prostate Testicular Urethral

Research Interests:

Novel therapies for breast and urothelial cancer

About Ellis Levine

Positions

Roswell Park Comprehensive Cancer Center

  • Professor of Oncology
  • Chief, Breast Medicine
  • Hematology/Medical Oncology Fellowship Director
  • Department of Medicine

Jacobs School of Medicine and Biomedical Sciences, University at Buffalo

  • Professor of Medicine
  • Director, Hematology/Medical Oncology Fellowship Program

Background

Education and Training:

  • MD - University of Pittsburgh, Pittsburgh, PA

Residency:

  • University of Minnesota, Minneapolis, MN

Fellowship:

  • University of Minnesota, Minneapolis, MN

Board Certification:

  • Internal Medicine, American Board of Internal Medicine
  • Medical Oncology, American Board of Internal Medicine

Honors & Awards:

  • 2005-2023 - America’s Top Doctors
  • 2018 - Susan G. Komen Hope Award for Upstate New York
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Learn More
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Learn More
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Learn More

Clinical Trials

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
Learn More
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Learn More
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
Learn More
Breast cancer at 32: Sheila's story Breast Cancer in Young Women: Family History Is the Best Indicator of Risk Can Breast Cancer Return After a Double Mastectomy? Prostate Cancer Survivor: Denny's Story Breast Cancer in Men: Owen’s Story What Happens If My Cancer Treatment Stops Working? How Research Saved My Life Detours and Delays, Then a New Route to Happiness What Happens When Pregnancy and Cancer Collide?

Featured on Cancer Talk

Breast cancer at 32: Sheila's story
Breast Cancer in Young Women: Family History Is the Best Indicator of Risk
Can Breast Cancer Return After a Double Mastectomy?

Showing all3 of 9

Publications

Full Publications list on PubMed

Agarwal N, Tangen CM, Hussain MHA, Gupta S, Plets M, Lara PN, Harzstark AL, Twardowski PW, Paller CJ, Zylla D, Zibelman MR, Levine E, Roth BJ, Goldkorn A, Vaena DA, Kohli M, Crispino T, Vogelzang NJ, Thompson IM Jr, Quinn DI. Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). J Clin Oncol. 2022 Oct 1;40(28):3301-3309. doi: 10.1200/JCO.21.02517. Epub 2022 Apr 21. PMID: 35446628; PMCID: PMC9553390.

Alaklabi S, Roy AM, Attwood K, George A, O'Connor T, Early A, Levine EG, Gandhi S. Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: A single institution experience. Front Oncol. 2022 Oct 20;12:1012391. doi: 10.3389/fonc.2022.1012391. PMID: 36338738; PMCID: PMC9631302.

Gandhi S, Opyrchal M, Grimm MJ, Slomba RT, Kokolus KM, Witkiewicz A, Attwood KM, Groman A, Williams l, Tarquini ML, Wallace PK, Soh KT, Minderman H, Mcguire O, O’Connor TL, Early AP, Levine EG, Kalinski P (2022) Systemic IFN-a/TLR3-Ligand Combination Reprograms Local Microenvironments of Breast Cancer Lesions for Selective CTL Influx. Submitted.

Ademuyiwa FO, Northfelt DW, O'Connor T, Levine E, Luo J, Tao Y, Hoog J, Laury ML, Summa T, Hammerschmidt T, Guo Z, Frith A, Weilbaecher K, Opyrchal M, Aft R, Clifton K, Suresh R, Bagegni N, Hagemann IS, Iglesia MD, Ma CX. A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN). NPJ Breast Cancer. 2023 Jan 6;9(1):1. doi: 10.1038/s41523-022-00504-z. PMID: 36609389; PMCID: PMC9822956.

Abraham A, Barcenas CH, Bleicher RJ, Cohen AL, Javid SH, Levine EG, Lin NU, Moy B, Niland JC, Wolff AC, Hassett MJ, Asad S, Stover DG. Clinicopathologic and sociodemographic factors associated with late relapse triple negative breast cancer in a multivariable logistic model: A multi-institution cohort study. Breast. 2023 Feb;67:89-93. doi: 10.1016/j.breast.2023.01.004. Epub 2023 Jan 17. PMID: 36681001.